Medical Research and Clinical Trials Involving People with Disabilities

People with disabilities represent roughly 26 percent of the U.S. adult population (CDC, Disability and Health Data System), yet for decades they were systematically excluded from the clinical trials meant to produce the treatments they often need most. That gap — between who gets studied and who gets treated — shapes everything from drug dosing guidelines to rehabilitation protocols. This page examines how medical research involving people with disabilities is structured, regulated, and sometimes gets it right or wrong.

Definition and scope

Medical research involving people with disabilities spans a wide range of inquiry: pharmaceutical trials, device testing, behavioral interventions, rehabilitation science, and health services research. The common thread is that participants have a physical, sensory, intellectual, or psychiatric condition that qualifies as a disability under frameworks like the Americans with Disabilities Act — meaning a substantial limitation on one or more major life activities.

The scope matters because disability is not monolithic. The types of disability relevant to research include mobility impairments, sensory disabilities, intellectual and developmental disabilities, traumatic brain injury, psychiatric conditions, and autism spectrum disorder, among others. Each category introduces distinct methodological considerations — from how informed consent is obtained to how outcome measures are calibrated.

Regulatory jurisdiction over this research sits primarily with three bodies: the Department of Health and Human Services (HHS), which administers the Common Rule at 45 CFR Part 46; the Food and Drug Administration (FDA), which governs trials involving investigational drugs and devices under 21 CFR Parts 50 and 56; and the Office for Human Research Protections (OHRP), which provides interpretive guidance and oversight. For research involving people with intellectual disabilities specifically, additional scrutiny under the Common Rule's "vulnerable populations" provisions applies.

How it works

Clinical trials and health research operate in phases, each with distinct risk-benefit thresholds.

1. Protocol development — Investigators design the study, define eligibility criteria, and identify outcome measures. This is where exclusion of people with disabilities most often happens silently: exclusion criteria written as "no significant comorbidities" or "able to complete written questionnaires" can quietly lock out entire disability subgroups.

2. Institutional Review Board (IRB) review — Every federally funded or FDA-regulated trial must undergo IRB review before enrollment begins. IRBs evaluate whether the consent process is accessible — including whether alternative formats (audio, simplified language, supported decision-making) are available for participants with cognitive or communication disabilities.

3. Informed consent — For participants with intellectual or cognitive disabilities, consent procedures may require legally authorized representatives, but research ethics frameworks emphasize that assent from the participant themselves remains meaningful and should be sought. OHRP guidance distinguishes capacity-based consent from blanket proxy substitution.

4. Enrollment and data collection — Accessibility of trial sites, equipment, and data collection instruments becomes a concrete operational issue here. A trial measuring cardiovascular fitness that relies on a standard treadmill protocol may produce systematically invalid data for participants with spinal cord injuries or lower-limb amputations.

5. Analysis and reporting — FDA guidance issued in 2012 and updated incrementally since has encouraged sponsors to analyze and report subgroup data by disability status, though this remains inconsistently implemented across industry-sponsored trials.

The National Institutes of Health (NIH) policy on inclusion of individuals across the lifespan, codified in the NIH Inclusion Policy, requires that women, minorities, and people across age groups be included in federally funded research — but disability status has not historically appeared as an explicit required inclusion category on par with those demographic factors.

Common scenarios

Three patterns recur across the research landscape:

Rehabilitation and assistive technology trials — Studies evaluating assistive technology or rehabilitation medicine interventions by definition involve people with disabilities as the primary population. These trials tend to have better-adapted protocols but often struggle with small sample sizes because the population of interest is clinically specific.

Pharmaceutical trials with disability-adjacent populations — A trial for a pain management drug may enroll participants with musculoskeletal conditions that overlap with disability and pain management — but if the trial's primary endpoints don't include functional disability measures, the resulting label may be silent on relevance to people with significant functional limitations.

Mental health and psychiatric research — Trials involving people with psychiatric disabilities face layered complexity: fluctuating decision-making capacity, stigma-driven underreporting, and the historical misuse of institutionalized populations in research (documented in accounts including the Tuskegee and Willowbrook studies, the latter involving children with intellectual disabilities).

Decision boundaries

The ethical and regulatory lines that govern this research are genuinely contested in places, but some boundaries are clear.

Inclusion vs. exclusion calculus — Excluding people with disabilities from a trial requires specific scientific justification. Convenience, liability concerns, or assumptions about compliance are not adequate grounds under either the Declaration of Helsinki or FDA's guidelines on inclusion. That said, safety considerations — for example, excluding individuals with severe renal impairment from a trial of a renally-cleared drug — are legitimate when documented.

Consent and capacity — Diminished decision-making capacity does not automatically disqualify someone from research participation. The distinction drawn by both OHRP and bioethics literature is between lacking capacity for a specific decision at a specific time versus a blanket assumption of incompetence based on diagnosis. People with intellectual and developmental disabilities have been historically over-excluded on this basis.

Risk categorization — The Common Rule distinguishes minimal risk research from greater-than-minimal risk research, with progressively stricter oversight requirements. Research involving people with disabilities that offers no prospect of direct benefit to participants must clear a higher bar for IRB approval, specifically under 45 CFR §46.405 for research involving children with disabilities under IDEA-adjacent frameworks.

Health equity intersections — Disability does not exist in isolation. As documented in research on disability and race and disability and poverty, people with disabilities who also belong to historically marginalized racial or socioeconomic groups face compounded barriers to trial access — geographic, financial, and systemic. The regulatory context surrounding research ethics continues to evolve in response to these documented inequities.